Evidence map›Paper›PMID 41312628›Full record

ArticleNucleic acids research2026

CellMiner cross-database (CellMinerCDB) version 2.2 for explorations of patient-derived cancer cell line pharmacogenomics.

Fathi Elloumi, William C Reinhold, Sudhir Varma, Yanghsin Wang, Meric Kinali, Yasuhiro Arakawa, Yoshitaka Inoue, Mirit I Aladjem, Yves Pommier, Augustin Luna

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Fathi ElloumiDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.ORCID 0009-0007-7116-508X
William C ReinholdDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.
Sudhir VarmaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.
Yanghsin WangDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.
Meric KinaliComputer Science Department, University of Massachusetts Boston, Boston MA 02125, United States.
Yasuhiro ArakawaDepartment of Clinical Pharmacology and Therapeutics, Jikei University School of Medicine, Tokyo 105-8461, Japan.
Yoshitaka InoueDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.
Mirit I AladjemDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.ORCID 0000-0002-1875-3110
Yves PommierDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.ORCID 0000-0002-3108-0758
Augustin LunaDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20814, United States.

Funding

Computational Analysis of Drug Response in Biological NetworksZIALM240126 · NLM · NATIONAL LIBRARY OF MEDICINE · PI LUNA, AUGUSTIN · 2024 to 2025
$1.8M
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Intramural NIH HHS Z01 BC006150Intramural NIH HHS ZIA LM240126NIH HHS Z01-BC 006150NIH HHS ZIALM240126NLM NIH HHS ZIALM240126
6 · The paper itself

Abstract

CellMiner Cross-Database (CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is an established interactive application providing direct access and enabling exploration of cancer cell line pharmacogenomics without extensive programming experience. Data are compiled from many sources, including the National Cancer Institute(NCI), Broad Institute Dependency Map (DepMap), Sanger/MGH Genomics of DrugSensitivity in Cancer (GDSC), MD Anderson Cell Lines Project (MCLP), andNational Center for Advancing Translational Sciences (NCATS). In the version 2.2 update, our collection has expanded to pharmacogenomics data for 1916 cancer cell lines and over 25 000 drugs. Drug screening data include many additional compounds for potential drug repurposing from the Broad PRISM, NCATS, and NCI. The user interface facilitates uncovering specific samples of interest and identifying drug and cell lines across databases. We also expanded the annotations for cross-referencing other databases and downloading our data for further cancer biology and drug discovery studies. Herein, we provide use cases for CellMinerCDB, including (i) data reproducibility given overlaps of cell lines, genes, and drugs across databases; (ii) candidate biomarker discovery; and (iii) cross-dataset analyses.

Indexed as

Antineoplastic AgentsDatabases, GeneticNeoplasmsPharmacogeneticsCell Line, TumorDrug RepositioningHumansInternetSoftwareUser-Computer InterfaceAntineoplastic Agents

Identifiers

PMID41312628
PMCPMC12807703

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.